RecruitingPHASE1, PHASE2NCT07169734
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alentis Therapeutics AG
- Intervention
- ALE.P03(drug)
- Enrollment
- 180 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (28)
- Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
- Norton Cancer Institute - Norton Healthcare Pavilion, Louisville, Kentucky, United States
- John Theurer Cancer Center, Hackensack, New Jersey, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Next Oncology-Oncology, San Antonio, Texas, United States
- NEXT Oncology Virginia, Fairfax, Virginia, United States
- Institut Gustave Roussy (IGR), Villejuif, France
- Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK), Hong Kong, Hong-Kong, Hong Kong
- Ospedale San Raffaele, IRCCS - Oncologia Medica, Milan, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- IEO - Istituto Europeo di Oncologia, IRCCS, Milan, Italy
- Radboudumc - Centrum voor Oncologie, Nijmegen, Netherlands
- National University Hospital (NUH) - Medical Oncology, Singapore, Singapore
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07169734 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University